第一章总则 第一条 为提高海利尔药业集团股份有限公司（以下简称"公司"）规范 运作水平，加大对信息披露责任人的问责力度，提高年报信息披露质量和透明度， 保证披露信息的真实、准确、完整、及时、公平，根据《中华人民共和国公司法》、 《中华人民共和国证券法》、中国证券监督管理委员会（以下简称"中国证监会"） 《上市公司信息披露管理办法》、《上海证券交易所股票上市规则》等相关法律、 法规、规范性文件及《海利尔药业集团股份有限公司章程》（以下简称"《公司 章程》"）、《海利尔药业集团股份有限公司信息披露管理制度》（以下简称"《公 司信息披露管理制度》"）的规定，特制订本制度。 海利尔药业集团 年报信息披露重大差错责任追究制度 海利尔药业集团股份有限公司 年报信息披露重大差错责任追究制度 第二条 本制度所称责任追究，是指年报信息披露工作中由于相关人员不 履行或不正确履行职责或由于其他个人原因，对公司造成重大经济损失或造成不 良社会影响时的追究与处理制度。 第三条 本制度所称年报信息披露的重大差错，包括年度财务报告存在重 大会计差错、其他年报信息披露存在重大错误或重大遗漏、业绩预告或业绩快报 存在重大差异等情形，或出现被证 ...

海利尔药业集团股份有限公司 关联交易决策制度 海利尔药业集团 关联交易决策制度 海利尔药业集团股份有限公司 关联交易决策制度 第一章 总则 第一条 为规范海利尔药业集团股份有限公司（下称"公司"）的关联交易， 保护公司、股东和债权人的合法权益，保证公司关联交易决策行为的公允性，根 据《中华人民共和国公司法》（下称"《公司法》"）、《中华人民共和国证券法》（下 称"《证券法》"）、《上海证券交易所股票上市规则》（下称"《上市规则》"）、《上 海证券交易所上市公司自律监管指引第 5 号——交易与关联交易》等有关法律、 法规、规范性文件和《海利尔药业集团股份有限公司章程》（下称"《公司章程》"） 的规定，制订本制度。 第二条 公司交易与关联交易行为应当定价公允、审议程序合规、信息披露 规范。 第三条 公司董事会下设的审计委员会，履行公司关联交易控制和日常管理 的职责。 第二章 关联人及关联交易认定 二〇二五年四月 海利尔药业集团 关联交易决策制度 （四） 持有公司 5%以上股份的法人或其他组织及其一致行动人； （五） 中国证监会、上海证券交易所或公司根据实质重于形式的原则认定 的其他与公司有特殊关系，可能或者已经造 ...

海利尔药业集团股份有限公司 海利尔药业集团股份有限公司董事会 2025 年 4 月 28 日 根据中国证券监督管理委员会《上市公司独立董事管理办法》《上海证券交易 所上市公司自律监管指引第 1 号——规范运作》等要求，海利尔药业集团股份有限 公司（以下简称"公司"）董事会结合独立董事出具的《海利尔药业集团股份有限 公司独立董事关于独立性自查情况的报告》，就公司在任独立董事的独立性情况进 行评估，出具如下专项意见： 公司独立董事符合《上市公司独立董事管理办法》《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等法律法规及《海利尔药业集团股份有限公司 章程》中关于独立董事的任职资格及独立性的要求，不存在任何妨碍其进行独立客 观判断的关系，不存在影响独立董事独立性的情况。 董事会关于独立董事独立性自查情况的专项报告 ...

海利尔药业集团股份有限公司 投资者关系管理档案制度 第一章 总 则 第一条 为加强海利尔药业集团股份有限公司（以下简称"公司"）投资者 关系管理的档案归档、管理工作，有效地保护和利用档案，维护公司合法权益， 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》 （以下简称《证券法》）、《上市公司治理准则》《上市公司信息披露管理办法》《上 海证券交易所股票上市规则》《上市公司投资者关系管理工作指引》《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》等有关法律、法规的规定和《海 利尔药业集团股份有限公司章程》（以下简称《公司章程》），制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对 上市公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、 回报投资者、保护投资者目的的相关活动。 第三条 投资者关系管理工作应严格遵守《公司法》《证券法》等有关法律、 法规及中国证监会、上海证券交易所有关业务规则的规定。 第四条 投资者关系管理工作应体现公平、公正、公开原则，平等对 ...

Financial Performance - The company's operating revenue for 2024 was CNY 3,907,553,145.61, a decrease of 11.16% compared to CNY 4,398,440,072.42 in 2023[23]. - The net profit attributable to shareholders for 2024 was CNY 181,372,732.58, down 61.67% from CNY 473,202,442.19 in 2023[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 163,198,596.07, a decline of 66.87% compared to CNY 492,632,801.10 in 2023[23]. - Cash flow from operating activities for 2024 was CNY 285,551,955.88, a significant drop of 70.11% from CNY 955,352,084.08 in 2023[23]. - Basic earnings per share for 2024 were 0.53 RMB, a decline of 61.87% from 1.39 RMB in 2023[24]. - The weighted average return on equity for 2024 was 5.30%, down from 14.49% in 2023, representing a decrease of 9.19 percentage points[24]. Audit and Compliance - The financial report has been audited by Zhongxinghua Accounting Firm, which issued a standard unqualified opinion[5]. - The board of directors and supervisory board members confirmed the authenticity, accuracy, and completeness of the annual report[3]. - The company has committed to ensuring the financial report's authenticity and accuracy through its responsible personnel[5]. - The internal control audit was conducted by Zhongxinghua Accounting Firm, resulting in a standard unqualified opinion report[199]. - The company has effectively implemented internal controls over its subsidiaries, with no significant deficiencies reported[198]. Risk Management - The company reported no significant risks affecting its production and operations during the reporting period[10]. - The company has outlined various risks and countermeasures in the management discussion section of the report[10]. - The company has not violated decision-making procedures for external guarantees[8]. - There were no non-operating fund occupations by controlling shareholders or related parties[8]. Market and Product Development - The company is actively expanding its international market presence and enhancing cooperation with multinational companies[31]. - New product developments include the trial production of several pesticide active ingredients, with projects entering trial production in 2024[32]. - The company has introduced several new pesticide products, including the insecticides Thiamethoxam and Acetamiprid, which are expected to enhance market competitiveness and drive revenue growth[38]. - The company’s main active ingredient products include insecticides and fungicides, with a focus on diversifying and enriching its pesticide offerings[38]. - The market for biopesticides, such as Abamectin, is expected to grow significantly, reflecting a broader trend towards environmentally friendly agricultural practices[43]. Strategic Initiatives - The company is focusing on cost reduction and efficiency improvement to enhance market competitiveness[31]. - The company plans to continue its dual-driven strategy of integrating active ingredients and formulations while expanding both domestic and international markets[64]. - The company is committed to reducing the use of chemical pesticides, targeting a coverage rate of 45% for integrated pest management in major grain crops by 2025[131]. - The company aims to achieve sales growth and cost control by 2025, while accelerating qualification construction in pesticide registration and GLP testing[143]. Governance and Management - The governance structure is continuously improved to ensure compliance with laws and protect shareholder rights, with independent oversight from the board and supervisory committee[155]. - The company maintains independence from its controlling shareholders, ensuring no interference in its operations and adherence to legal obligations[156]. - The company emphasizes transparency in information disclosure, ensuring all shareholders have equal access to relevant information[158]. - The company has established a talent training program focusing on new employees and ongoing professional development for existing staff[182]. Shareholder Returns - The profit distribution plan for 2024 proposes a cash dividend of 5 RMB per 10 shares (including tax), subject to shareholder approval[6]. - The company plans to distribute a cash dividend of 5 RMB (including tax) for every 10 shares, with a total cash dividend amounting to 169,949,168 RMB, which represents 93.7% of the net profit attributable to ordinary shareholders in the consolidated financial statements[187][191]. - Over the last three accounting years, the cumulative cash dividend amount (including tax) reached 680,182,662 RMB, with an average annual net profit of 371,528,355.75 RMB, resulting in a cash dividend ratio of 183.08%[192]. Research and Development - The company has synthesized over 6,888 new compounds and achieved three lead compounds during the reporting period[102]. - The company has submitted 104 invention patent applications and achieved 58 new patent certifications during the reporting period[102]. - The company is committed to increasing R&D investment to develop high-efficiency, low-toxicity, and environmentally friendly pesticide formulations to achieve product differentiation[149]. Financial Management - The company has approved a comprehensive credit limit application for 2024, including corresponding guarantee limits[161]. - The company has approved the use of idle funds for purchasing financial products, enhancing financial management strategies[174]. - The total remuneration for directors and senior management during the reporting period amounted to 7.03 million yuan[163].

Financial Performance - The company's revenue for Q1 2025 reached ¥1,263,995,067.89, representing a year-on-year increase of 10.16% compared to ¥1,147,462,366.23 in the same period last year[4] - Net profit attributable to shareholders was ¥104,923,877.98, up 15.64% from ¥90,735,881.42 in the previous year[4] - Basic and diluted earnings per share increased to ¥0.31, reflecting a growth of 14.81% from ¥0.27[4] - The total operating revenue for Q1 2025 reached ¥1,263,995,067.89, an increase of 10.1% compared to ¥1,147,462,366.23 in Q1 2024[17] - The net profit for Q1 2025 was CNY 104,923,877.98, representing an increase of 15.1% compared to CNY 90,735,881.42 in Q1 2024[18] - The total comprehensive income for Q1 2025 was CNY 105,458,899.13, compared to CNY 90,750,801.43 in Q1 2024, indicating a growth of 16.2%[18] Cash Flow and Operating Activities - The net cash flow from operating activities improved significantly to -¥38,611,783.74, compared to -¥177,401,401.40 in the same period last year, indicating a substantial recovery[4] - The cash flow from operating activities for Q1 2025 was negative at CNY -38,611,783.74, an improvement from CNY -177,401,401.40 in Q1 2024[20] - The cash flow from investing activities for Q1 2025 was negative at CNY -17,023,037.76, compared to a positive CNY 158,908,781.68 in Q1 2024[21] - The cash flow from financing activities for Q1 2025 was positive at CNY 4,652,734.51, contrasting with a negative CNY -46,710,619.51 in Q1 2024[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,129,685,212.60, a 3.87% increase from ¥6,864,016,889.81 at the end of the previous year[5] - The total liabilities increased to ¥3,597,348,468.55 from ¥3,440,203,095.45, indicating a rise of 4.6%[15] - Total assets as of March 31, 2025, were ¥7,129,685,212.60, up from ¥6,864,016,889.81 at the end of 2024, reflecting a growth of 3.9%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period was 12,006[9] - The top shareholder, Zhang Aiying, holds 127,253,000 shares, representing 37.4% of the total shares, with a portion pledged[9] Profitability Metrics - The weighted average return on equity was 3.02%, up from 2.65% in the previous year, indicating improved profitability[5] - The gross profit for Q1 2025 was ¥142,466,339.14, compared to ¥136,414,578.54 in Q1 2024, indicating a growth of 4.0%[17] Expenses - The total operating costs for Q1 2025 were ¥1,123,528,728.75, up from ¥1,011,047,787.69 in Q1 2024, reflecting a year-over-year increase of 11.1%[17] - Research and development expenses for Q1 2025 amounted to ¥35,452,640.18, down 31.3% from ¥51,639,315.65 in Q1 2024[17] Other Financial Metrics - Non-recurring gains and losses totaled ¥9,454,247.54, with government subsidies contributing ¥5,285,970.94[6] - The company reported a decrease in asset impairment losses to CNY -4,338,184.11 in Q1 2025 from CNY -2,655,580.38 in Q1 2024[18] - The company's cash and cash equivalents decreased to ¥1,267,042,571.86 as of March 31, 2025, from ¥1,347,387,470.11 at the end of 2024, a decline of 5.9%[13] - Accounts receivable increased significantly to ¥1,168,344,166.43 from ¥873,216,631.07, representing a growth of 33.8%[13] - Inventory levels rose to ¥989,512,326.23, compared to ¥933,415,210.00 at the end of 2024, marking an increase of 6.0%[14]

问：海利尔如何响应"双碳目标""农业强国"等国家战略？ 葛尧伦：海利尔是一家集农业农药研发、生产、经营及技术服务于一体的大型农化集团。公司实施"原药制剂一体化、国内国际一体化"的双轮驱动战略，通 过开发高效、低毒、低残留农药及生物农药，筑牢食品安全与粮食安全的核心保障能力。在企业发展进程中，我们对标先进跨国企业，建立自主创新体系， 构建起具有国际竞争力的研发团队，国际业务已拓展至80多个国家和地区。 问：您曾说过"企业如果没有研发是没有未来的"。海利尔是如何凭借技术研发优势提升行业话语权的？ 问：您提出"不下田、就下岗"的口号，这种田间实验室模式是否保证了研发与市场需求紧密结合在一起的？ 葛尧伦：我们确立"从田间来，到田间去"的研发准则，确保技术落地，建立专业农服团队，直接获取种植户需求；构建验证体系，所有新产品需通过田间实 效测试，通过将科研人员考核与田间实效挂钩，真正实现"研发闭环始于农田，价值兑现归于农田"。例如，传统的药剂仅能维持三四天就会又起满虫子，海 利尔创制持效期达20天以上的新型化合物，通过科学用药指导，精准剂量使用到作物上，让种植大户切实感受到、看到、用到。农民的痛点是劳动力成本越 来越高， ...

证券代码：603639 证券简称：海利尔 公告编号：2025-008 海利尔药业集团股份有限公司 关于第五届董事会第七次会议决议的公告（修订版） 根据公司《2021 年限制性股票激励计划（草案）》（以下简称"本激励计划"） 和《考核管理办法》的相关规定，本激励计划预留授予部分的限制性股票第三个 限售期已符合要求且解除限售条件已经成就，根据公司 2021 年第一次临时股东 大会的授权，同意公司董事会按照本激励计划的相关规定办理第三期限制性股票 解除限售的相关事宜。本次符合解除限售条件的激励对象共 62 名，可解除限售 的限制性股票数量为 228,840 股（以中国证券登记结算有限责任公司实际登记数 量为准），占目前公司总股本的 0.0673%[注]。 本议案经公司董事会薪酬与考核委员会审议通过后提交董事会审议。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 海利尔药业集团股份有限公司(以下简称"公司")第五届董事会第七次会议 于 2025 年 2 月 24 日以通讯表决的方式召开。会议通知于 2025 ...

证券代码：603639 证券简称：海利尔 公告编号：2025-009 海利尔药业集团股份有限公司 关于2021年限制性股票激励计划预留授予部分 第三期解锁条件成就的公告（修订版） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司2021年限制性股票激励计划预留授予部分的限制性股票第三期解 锁条件已成就，符合解除限售条件的激励对象共62名，可解除限售的限制性股票 数量为228,840股（以中国证券登记结算有限责任公司实际登记数量为准），占 目前公司总股本的0.0673%[注]。 本次限制性股票待相关解除限售上市申请完成后，公司将发布相关解锁 暨上市的公告，敬请投资者注意。 2025 年 2 月 24 日，海利尔药业集团股份有限公司（以下简称"公司"）召 开第五届董事会第七次会议，审议通过了《关于 2021 年限制性股票激励计划预 留授予部分第三期解锁条件成就的议案》，现就相关事项说明如下： 一、股权激励计划限制性股票批准及实施情况 (一)限制性股票激励计划已履行的决策程序及信息披露情况 1、2021 年 3 ...

证券代码：603639 证券简称：海利尔 公告编号：2025-010 本次股票上市类型为股权激励股份；股票认购方式为网下，上 市股数为 228,840 股。 本次股票上市流通总数为 228,840 股。 本次股票上市流通日期为 2025 年 3 月 20 日。 海利尔药业集团股份有限公司 关于 2021 年限制性股票激励计划预留授予部分第三期 解锁暨股票上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 5、2021 年 5 月 12 日，公司披露了《关于 2021 年限制性股票激励计划首次授 予结果的公告》（公告编号：2021-034），确定限制性股票登记日为 2021 年 5 月 10 日，登记数量为 541.4 万股。 一、2021 年限制性股票激励计划批准及实施情况 (一)本激励计划已履行的决策程序及信息披露情况 1、2021 年 3 月 5 日，公司召开第四届董事会第三次会议和第四届监事会第三 次会议，审议通过《关于公司 2021 年限制性股票激励计划（草案）及其摘要的议 案》、《关于公司 ...